Ractigen Therapeutics’ RAG-18 Gains the US FDA’s Orphan Drug Designation to Treat DMD and BMD
Shots:
- The US FDA has granted orphan drug designation to the company’s RAG-18 for treating Duchenne Muscular Dystrophy (DMD) & Becker Muscular Dystrophy (BMD) caused by any mutation of the DMD gene
- RAG-18 is a saRNA candidate aimed at selectively stimulating UTRN gene expression in muscle cells through an RNA activation mechanism.
- Preclinical evidence suggests that RAG-18, which is administered via subcutaneous injection using Ractigen’s exclusive LiCO technology. Additionally, RAG-18 obtained RPDD from the US FDA in July of this year.
Ref: Ractigen Therapeutics | Image: Ractigen Therapeutics
Related News:- Amylyx Pharmaceuticals’ AMX0035 Gains the EC’s Orphan Drug Designation to Treat Wolfram Syndrome
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
